On 9 January 2020, orphan designation EU/3/19/2237 was granted by the European Commission to Emerald Health Pharmaceuticals Espana S.L, Spain, for 2-(3,7-dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone (also known as VCE-003.2) for the treatment of Huntington's disease.
Treatment of Huntington's disease
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
Emerald Health Pharmaceuticals Espana S.L.
Parque Científico Tecnológico de Córdoba (Rabanales 21)
C/ Astrónoma Cecilia Payne
Tel. + 34 6107 86932
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.